Dr. Dan explains the FDA approval of a new treatment combination for Multiple Myeloma patients. Article from February 2021.
In January 2021, Dr. Dan explains this new therapy option for relapsed or refractory mantle cell lymphoma patients.
In February 2021, the FDA approved a new treatment combination for unresectable malignant pleural mesothelioma patients and Gryt Health’s Chief Medical Officer, Dr. Dan breaks it down for us.
In February 2021, the FDA announced the approval of Onureg, a new oral formulation of a drug used for remission continuation therapy in adults with acute myeloid leukemia (AML). Gryt Health Chief Medical Officer breaks this down for our community.
Dr. Dan Platt breaks down what the December 2020 FDA approval for myelodysplatic syndromes treatment of dacogen and cedazuridine combination means for patients.
Dr. Dan, Chief Medical Officer at Gryt Health breaks down the approval of pralsetinib by the FDA for lung cancer patients with RET gene fusions.
Dr. Dan, Chief Medical Officer at Gryt Health, makes finding a clinical trial look easy so that our community can be informed decision makers and find a trial that suits their own needs.
Dr. Dan, Gryt Health’s Chief Medical Officer breaks down the takeaways of this new approval from January 2021.
As of December 2020, the Food and Drug Administration (FDA) has granted accelerated approval to Gavreto, the second drug for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). Gryt Health Chief Medical Officer, Dr. Dan breaks down the announcement.
From March 2021, Gryt Health Chief Medical Officer, Dr. Dan, lays out what cancer patients need to know about COVID and vaccination.
